$CSTL Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
on June 23, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
5:00 PM
Symbol:
CSTL
Source:
Business Wire
$CSTL Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
on June 22, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire
$CSTL Castle Biosciences Announces Support for OHSU’s War on Melanoma™
on June 20, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire
$CSTL Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
on June 14, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire
$CSTL Castle Biosciences to Present at the JMP Securities Life Sciences Conference
on June 8, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire
$CSTL Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
on May 27, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire
$CSTL Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
on May 25, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
5:00 PM
Symbol:
CSTL
Source:
Business Wire
$CSTL TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
on May 24, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
5:00 PM
Symbol:
CSTL
Source:
Business Wire
$CSTL Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
on May 20, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire
$CSTL Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
on May 19, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire
$CSTL Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
on April 18, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Castle Biosciences to Acquire AltheaDx
on April 4, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
4:05 PM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
on March 29, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
5:00 PM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
on March 25, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity
on March 11, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Castle Biosciences to Present at Upcoming Investor Conferences
on March 1, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results
on February 28, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
4:05 PM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
on February 14, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
on February 7, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
7:00 AM
Symbol:
CSTL
Source:
Business Wire News Releases
$CSTL Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
on January 13, 2022
News
and Tags: Castle Biosciences Inc, Castle Biosciences Inc News, CSTL, CSTL News
with 0 comments
Time:
5:00 PM
Symbol:
CSTL
Source:
Business Wire News Releases